Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report

Ken Takao 1†, Ayaka Tani 1†, Tetsuya Suwa 1*, Yayoi Kuwabara-Ohmura 1, Kenta Nonomura 1, Yanyan Liu 1, Takehiro Kato 1, Masami Mizuno 1, Takuo Hirota 1, Mayumi Enya 1, Katsumi Izuka 1, Yukio Horikawa 1, Chiemi Saigo 2, Yusuke Kito 2, Tatsuhiko Miyazaki 2, Naoyuki Ohe 3, Toru Iwama 3 and Daisuke Yabe 1*

Abstract

Background: Primary central nervous system lymphoma is a rare extra-nodal lymphoma of the central nervous system. Primary central nervous system lymphoma lesions usually appear in the vicinity of the ventricle, and there are few reports of primary central nervous system lymphoma with hypothalamic-pituitary lesions.

Case presentation: We treated a 56-year-old male with primary central nervous system lymphoma with the primary lesion in the hypothalamus, which was found by magnetic resonance imaging after sudden onset of endocrinological abnormalities. Initially, he was hospitalized to our department for hyponatremia. Endocrinological examination in conjunction with head magnetic resonance imaging and endoscopic biopsy revealed hypothalamic hypopituitarism and tertiary hypoadrenocorticism caused by a rapidly growing, diffuse large B-cell lymphoma in the hypothalamus. Remission of the tumor was achieved by high-dose methotrexate with whole brain radiotherapy, and some of the hormone responses were normalized.

Conclusions: While primary central nervous system lymphoma is rare, it is important to note that hypopituitarism can result and that the endocrinological abnormalities can be partially restored by its remission.

Keywords: PCNSL, Hypothalamus, Hypopituitarism, Case report

Background

Primary central nervous system lymphoma (PCNSL) is an extra-nodal lymphoma that shows no lesions other than in the central nervous system at the time of diagnosis [1]. While the disease is relatively rare, comprising 1–5% of brain tumors, the number of PCNSL cases is increasing recently [2, 3]. PCNSL is frequently found in association with acquired immunodeficiency syndrome (AIDS) in western countries; most PCNSL cases in Japan are without AIDS and tend to be found in individuals age 50–70 in whom the disease progresses from B lymphocytes [4]. PCNSL lesions usually appear in the vicinity of the ventricle, and are often multiple. Initial symptoms may include subclinical intracranial pressure and psychiatric conditions in addition to other conditions originating in the brain such as paralysis and aphasia [5]. PCNSL with hypothalamic-pituitary lesions has been rarely reported [6]. Here we report a case of PCNSL with the primary lesion in the hypothalamus, which
was found by magnetic resonance imaging (MRI) after sudden onset of endocrinological abnormalities.

**Case presentation**

At 56 years of age, the patient was diagnosed with Connshing syndrome and received laparoscopic left adrenalectomy at another medical institution. He then started receiving hydrocortisone (HC) replacement and was monitored for ACTH and cortisol levels. He was also diagnosed with an old myocardial infarction and started receiving aspirin (100 mg/day). At 57 year of age, he was transferred to our hospital due to his residential relocation. When he visited our hospital for the first time, his ACTH and cortisol ≥24 h after taking 2.5 mg HC the previous morning were 48.6 pg/ml and 15.2 μg/dl, respectively, and his HC replacement was terminated.

Three months later, he began to suffer from blurred vision, headache and appetite loss, and was admitted to the emergency department of our institution. His height and body weight were 164.8 cm and 76.3 kg, respectively. His vital signs were normal (blood pressure, 129/93 mmHg; pulse 82 bpm; body temperature 36.7 °C; SpO2 96%) and he showed no abnormalities in neurological or physical examinations that we routinely perform in clinical practice. However, his serum sodium concentration was 106 mEq/L and plasma osmolality was 217 mOsm/kgH2O (Tables 1 and 2), and he was then hospitalized to our department. After hospitalization, his hyponatremia was corrected by intravenous and oral administration of sodium chloride, which, together with HC replacement from the 3rd day after hospitalization, improved his blurred vision, headache and appetite loss. In the morning of the 2nd day after hospitalization, levels of TSH, ACTH, GH, LH and FSH were low, and that of PRL was high (Table 3). On the 2nd day after hospitalization, his urinary cortisol was ≤15.5 μg/dL, while plasma levels of ACTH (pg/mL) and cortisol (μg/dl) were as follows: 8 am, 17.5 and 1; 2 pm, 13.7 and 1; 8 pm 14.1 and 1.1; and 11 pm 8.8 and 0.8, respectively. Little TSH and GH response was observed in TRH and GHRP-2 stimulation tests, respectively (Fig. 1a and d). Near normal LH and FSH responses were observed in GnRH stimulation test (Fig. 1b), but basal levels of LH and FSH were low (Table 3). Hyper ACTH response with low cortisol response was observed in CRH stimulation test (Fig. 1c). ACTH response was delayed with a low cortisol response and little GH response in insulin stimulation test (Fig. 1e). Peak cortisol level was <18 μg/dL in ACTH rapid stimulation test, which was carried out ≥24 h after administration of 10 mg HC (Fig. 1f). These results indicated the presence of hypothalamic hypopituitarism and tertiary hypoadrenocorticism. The patient then experienced atypical visual field loss in his right eye. His MRI on day 14 after hospitalization revealed a rapidly growing tumor in the hypothalamus (Fig. 2a) that was absent 1 year before. Endoscopic biopsy of the tumor using a

| Biochemistry | Complete blood count |
|--------------|---------------------|
| Total protein | 7.6 g/dL | Cre | 0.48 mg/dL |
| Albumin | 4.5 g/dL | BUN | 5.3 mg/dL |
| CPK | 358 U/L | Total-cho | 171 mg/dL |
| AST | 46 U/L | HDL-cho | 30 mg/dL |
| ALT | 77 U/L | TG | 205 mg/dL |
| LDH | 211 U/L | Na | 106 mmol/L |
| ALP | 415 U/L | K | 4.2 mmol/L |
| γ-GTP | 115 U/L | Cl | 77 mmol/L |
| CHE | 275 U/L | Ca | 9.2 mg/dL |
| AMY | 42 U/L | IP | 2.4 mg/dL |
| UA | 2.3 mg/dL | BNP | 42.9 pg/mL |
| CRP | 0.74 mg/dL | Glu | 127 mg/dL |

**Table 2** Urinalysis upon admission to our emergency department

| Specific gravity | 1.011 |
| pH | 6.0 |
| Protein | – |
| Glucose | – |
| Ketone body | + |
| Blood | + |
| Osmolarity | 439 mOsm/kgH2O |
| Na | 148 mEq/L |
| K | 36.6 mEq/L |
| Cl | 128 mEq/L |
ventriculoscope revealed a proliferation of atypical lymphocytes, which was positive for CD20 and CD79a (Fig. 3) as well as CD10 and Bcl-6 but negative for Bcl-2 (data not shown). The MIB-1 index was approximately 80% (Fig. 3). These results together suggested B-cell lymphoma. His serum level of soluble IL-2 receptor was 436.0 U/mL (normal range, 122–496 U/mL), and examination of cerebrospinal fluid revealed no abnormalities.

He then started 6 courses of high-dose methotrexate (3.5 g/m²) with stereotactic radiotherapy without whole brain radiotherapy (20 Gy) along with oral administration of HC (15 mg/day) and levothyroxine (25 μg/day), which resulted in remission of the tumor (Fig. 2b). Some of the hormone responses (i.e., ACTH, TSH, PRL, LH and FSH), which were determined were normalized (Fig. 1).

Eight months after the initial hospitalization, he had a relapse of the tumor and received 3 courses of high dose methotrexate (5 g/m²) with stereotactic radiotherapy without whole brain radiotherapy (20 Gy) along with oral administration of HC (15 mg/day) and levothyroxine (25 μg/day), which resulted in remission of the tumor (Fig. 2b). Some of the hormone responses (i.e., ACTH, TSH, PRL, LH and FSH), which were determined were normalized (Fig. 1).
methotrexate with whole brain radiotherapy (23.4 Gy), which resulted in another remission of the tumor. Twenty-two months after the initial hospitalization, he was hospitalized due to profound hyperthermia and disturbance of consciousness. Investigations including head MRI failed to find a cause of the hyperthermia, and hypothalamic dysfunction was suspected. His body temperature was high during summer and low during winter (Fig. 4a). He had increased appetite likely due to hypothalamic dysfunction, which resulted in body weight gain and fatty liver (Fig. 4b and c). He then started showing a gradual decline in cognitive function and activities of daily living. His head MRI at regular checkup revealed recurrence of the PCNSL at 38 months after the initial hospitalization; the patient died 39 months after the initial hospitalization.

Discussion and conclusions
Here we present a case of PCNSL with the primary lesion in the hypothalamus, which was found by MRI and assumed to be the cause of his hypopituitarism. While the patient’s age and pathological findings are consistent with typical PCNSL cases, this case is exemplified by hyponatremia due to hypoadrenocorticism, which together prompted the diagnosis and reflect the localization of the tumor. PCNSL with hypothalamic-pituitary lesions is extremely rare [7]. Symptoms of hypopituitarism may appear suddenly and quickly worsen as the tumor grows rapidly, as in the current case [8]. Indeed, we found a rapid decline in adrenal cortical function over a relatively short period of about 3 months. Importantly, secretions of some pituitary hormones (e.g., ACTH, TSH, PRL, LH and FSH) during

Fig. 2 Imaging analysis before and after the treatment of the central nervous system lymphoma. a, b. Gadolinium-enhanced magnetic resonance imaging (MRI) before and after the initial treatment of the patient's central nervous system lymphoma. A 16 × 12 mm lobulated tumor mass in the hypothalamus that extends to the pituitary stalk and the right temporal lobe was detected as a low intensity mass in T2-weighted imaging, a faint high intensity mass in diffusion-weighted imaging, and fluid attenuated inversion recovery imaging (a). The mass was no longer detected after the treatment (b). T1, T1-weighted imaging; T2, T2-weighted imaging; DWI, diffusion-weighted imaging; FLAIR, fluid attenuated inversion recovery imaging; Sag, sagittal plane; Cor, coronal plane.
Fig. 3 Pathological analysis of the patient’s tumor. The analysis found proliferation of atypical lymphocytes that were positive for CD20 and CD79a. MIB-1 index was approximately 80%. Magnification × 400.

Fig. 4 Changes of body temperature, body weight and serum levels of alanine aminotransferase (ALT) and computer tomography (CT) images of the patient’s liver. 

A. Body temperature

B. Bodyweight and ALT

C. CT images of the liver

Fig. 4 Changes of body temperature, body weight and serum levels of alanine aminotransferase (ALT) and computer tomography (CT) images of the patient’s liver. 

A. His body temperature changed with the rise and fall of the ambient temperature, likely due to the impaired thermoregulatory center. 

B. His body weight and ALT level gradually became elevated, likely due to dysregulated appetite. 

C. The ratio of his liver-to-spleen (L/S) Hounsfield units on CT scan gradually declined (+1 month, 0.96; +22 months, 0.42; and +35 months, 0.37), likely due to worsening fatty liver (months after the initial hospitalization to our institution are shown as +X month(s)).
various stimulation tests were partially improved by remission of the tumor, further suggesting infiltration and displacement of the hypothalamus and pituitary stalk as the cause of hypopituitarism in this case.

Risk factors for PCNSL include chronic use of immunosuppressants for organ transplants and autoimmune diseases in addition to immunodeficiency associated with HIV infection [9, 10]. While the current case had been on HC replacement therapy before admission to our institution, because of the short duration and low dosage it is not likely that he was immunosuppressed. We did not investigate genetic alterations in the current case, but previous studies have shown the B-cell receptor pathway, which involves MYD88, CD79B and NF-kB activation, to be critical in the pathogenesis of PCNSL [11]. In conclusion, we treated a case of PCNSL with the primary lesion in the hypothalamus, which was found by MRI after sudden onset of endocrinological abnormalities. While PCNSL is rare, it is important to note that hypopituitarism can be caused by the disease and that endocrinological abnormalities can be partially restored by its remission.

Abbreviations
AIDS: Acquired Immunodeficiency syndrome; MRI: Magnetic resonance imaging; PCNSL: Primary central nervous system lymphoma; HC: Hydrocortisone

Acknowledgements
The authors also thank J. Kawada and M. Kato for their technical assistance, and M. Yato, Y. Ogiso and M. Nozu for their secretarial assistance.

Authors’ contributions
KT, AT, TS and DY contributed to the analysis, collection, and interpretation of data and writing of the manuscript. YK, KN, YL, TK, MM, TM, NO, and TI contributed to the analysis, collection, and interpretation of data and critical revisions of the manuscript for important intellectual content. All authors approved the version to be published. DY and TS are the guarantors of this work.

Funding
This work was supported by grants from Japan Society for the Promotion of Sciences (JSPS) [KAKENHI Grant 17K09825 (to D.Y.), 17K0850 (to K.I) and 18H02779 (to Y.H.)].

Availability of data and materials
Clinical data from the corresponding author will be available upon request.

Ethics approval and consent to participate
Formal ethics approval was waived from the ethics committee of Gifu University Graduate School of Medicine because of a case report.

Consent for publication
Written informed consent was obtained from the family for publication of this report as the patient deceased 38 months after the initial diagnosis of PCNSL.

Competing interests
The authors declare that they have no competing interests associated with this study.

Author details
1Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan. 2Division of Pathology, Gifu University Hospital, Gifu, Japan.

References
1. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–8.
2. Brain Tumor Registry of Japan (2005–2008). Neurol Med Chir (Tokyo). 2017;57(Suppl 1):91–102.
3. DelWitt JC, Mock A, Louis DN. The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol. 2017;30(6):643–9.
4. Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177–86.
5. Li L, Rong JH, Feng J. Neuroradiological features of lymphomatosis cerebri: a systematic review of the English literature with a new case report. Oncol Lett. 2018;16(2):1463–74.
6. Tanki HN, Malik KN, Mahkdoomi R, Feroz S, Ramzan AU. Primary hypothalamic lymphoma in an adult male: a case report and literature review. Oman Med J. 2018;33(4):436–51.
7. Kuker W, Nagele T, Kofiel A, Hecht S, Thiel E, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neuro-Oncol. 2005;72(2):169–77.
8. Giustina A, Gola M, Doga M, Rosi E. Clinical review 136: primary hypopituitarism of the pituitary: an emerging clinical entity. J Clin Endocrinol Metab. 2001;86(10):4567–75.
9. Villano JL, Kosty M, Shalik H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–8.
10. Su L, Ding M, Chen L, Li C, Lao M. Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: a case report and review of literature. Medicine (Baltimore). 2018;97(23):e11072.
11. Tsang M, Cleveland J, Rubenstein JL. On point in primary CNS lymphoma. Hematol Oncol. 2000;18(5):560–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.